067630 HLB생명과학
기본 정보
- 섹터: KOSDAQ:제조
- 시가총액: 3,986억원 (2026-06-30 기준)
- 첫 등장: — (마커 미등장)
- 태그: 매크로/바이오헬스 · 매크로/전력에너지 · 의료기기 · 체외진단 · 신약 · 바이오 · 태양광
- 네이버 금융: 🔗
기업개요
- 동사는 1998년 설립되어 2008년 코스닥시장에 상장된 기업으로, 2023년 화진메디칼 합병 완료 후 2025년 티니코 지분 100%를 인수하여 의료기기사업을 확대함.
- 메디케어, 바이오개발, 의료기기, 에너지 등 4개 사업부문을 영위하고 있음.
- 체외진단 의료기기 OEM/ODM, 일회용 주사기 제조·판매, 바이오인공간 및 지혈제 개발, 태양광 EPC 및 폐기물 소각열 관련사업을 수행하고 있음.
출처: 네이버증권 종목분석 (WiseReport)
일자별 등장 (최신 위, 누적)
| 일자 | 전일 종가 | 종가 | 등락률 | 시간외 | vol | 색깔 | smart | 외 | 연 | 금투 | 투 | 개 | 그외 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-07 | 2,365 | 2,500 | 🔴 +5.71% | — | ×0.6 | 🟢 외인 | +1.8억 | +1.8 | +0.0 | +0.0 | +0.0 | -1.8 | +0.0 |
| 2026-08-06 | 2,290 | 2,365 | 🔴 +3.28% | — | ×0.4 | 🟢 외인 | +1.2억 | +1.2 | +0.0 | +0.0 | +0.0 | -1.2 | +0.0 |
| 2026-08-05 | 2,170 | 2,290 | 🔴 +5.53% | — | ×0.6 | 🟢 외인 | +0.9억 | +0.9 | +0.0 | +0.0 | +0.0 | -0.9 | +0.0 |
| 2026-08-04 | 2,055 | 2,170 | 🔴 +5.60% | — | ×0.4 | 🟢 외인 | +1.7억 | +1.7 | +0.0 | +0.0 | +0.0 | -1.7 | +0.0 |
| 2026-08-03 | 2,020 | 2,055 | 🔴 +1.73% | — | ×0.2 | 🟢 외인 | +1.0억 | +1.0 | +0.0 | +0.0 | +0.0 | -1.0 | +0.0 |
| 2026-07-31 | 1,925 | 2,020 | 🔴 +4.94% | — | ×0.2 | 🟢 외인 | +1.2억 | +1.2 | +0.0 | +0.0 | +0.0 | -1.2 | +0.0 |
| 2026-07-30 | 2,020 | 1,925 | 🔵 -4.70% | — | ×0.2 | 🔻 개인 | -1.9억 | -1.9 | +0.0 | +0.0 | +0.0 | +1.9 | +0.0 |
| 2026-07-29 | 2,035 | 2,020 | 🔵 -0.74% | — | ×0.3 | 🔻 개인 | -0.7억 | -0.7 | +0.0 | +0.0 | +0.0 | +0.7 | +0.0 |
| 2026-07-28 | 2,200 | 2,035 | 🔵 -7.50% | — | ×0.2 | 🔻 개인 | -0.4억 | -0.4 | +0.0 | +0.0 | +0.0 | +0.4 | +0.0 |
| 2026-07-27 | 2,205 | 2,200 | 🔵 -0.23% | — | ×0.2 | 🔻 개인 | -0.4억 | -0.4 | +0.0 | +0.0 | +0.0 | +0.3 | +0.1 |
| 2026-07-24 | 2,045 | 2,205 | 🔴 +7.82% | — | ×2.4 | 🔻 개인 | -0.7억 | -0.7 | +0.0 | +0.0 | +0.0 | +0.7 | +0.0 |
| 2026-07-23 | 1,967 | 2,045 | 🔴 +3.97% | — | ×0.3 | 🔻 개인 | -0.7억 | -0.7 | +0.0 | +0.0 | +0.0 | +0.7 | +0.0 |
| 2026-07-22 | 2,045 | 1,967 | 🔵 -3.81% | — | ×0.5 | 🔻 개인 | -1.3억 | -1.3 | +0.0 | +0.0 | +0.0 | +1.3 | +0.0 |
| 2026-07-21 | 2,105 | 2,045 | 🔵 -2.85% | — | ×0.6 | 🔻 개인 | -2.3억 | -2.3 | +0.0 | +0.0 | +0.0 | +2.3 | +0.0 |
| 2026-07-20 | 2,380 | 2,105 | 🔵 -11.55% | — | ×0.7 | 🔻 개인 | -0.5억 | -0.5 | +0.0 | +0.0 | +0.0 | +0.3 | +0.1 |
| 2026-07-16 | 2,325 | 2,380 | 🔴 +2.37% | — | ×5.9 | 🔻 개인 | -3.7억 | -3.7 | +0.0 | -0.0 | -0.1 | +3.7 | +0.0 |
| 2026-07-15 | 1,791 | 2,325 | 🔴 +29.82% | — | ×2.4 | 🔻 개인 | -0.9억 | -0.9 | +0.0 | +0.0 | +0.0 | +0.9 | -0.0 |
| 2026-07-14 | 1,640 | 1,791 | 🔴 +9.21% | — | ×2.8 | 🟢 외인 | +4.4억 | +4.4 | +0.0 | +0.0 | +0.0 | -4.4 | +0.0 |
| 2026-07-13 | 2,230 | 1,640 | 🔵 -26.46% | — | ×17.4 | ⚫ 그외 | -0.2억 | -0.2 | +0.0 | +0.0 | +0.0 | -0.9 | +1.1 |
| 2026-07-10 | 3,180 | 2,230 | 🔵 -29.87% | — | ×1.4 | ⚫ 그외 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | -0.0 | +0.0 |
| 2026-07-09 | 3,065 | 3,180 | 🔴 +3.75% | — | ×1.4 | 🟢 외인 | +1.4억 | +1.3 | +0.0 | +0.0 | +0.1 | -1.6 | +0.3 |
| 2026-07-08 | 3,145 | 3,065 | 🔵 -2.54% | — | ×0.7 | 🔻 개인 | -0.9억 | -0.9 | +0.0 | +0.0 | +0.0 | +0.9 | +0.0 |
| 2026-07-07 | 3,125 | 3,145 | 🔴 +0.64% | — | ×0.8 | 🔻 개인 | -0.9억 | -0.9 | +0.0 | +0.0 | +0.0 | +0.9 | +0.0 |
| 2026-07-06 | 3,110 | 3,125 | 🔴 +0.48% | — | ×0.6 | 🟢 외인 | +0.1억 | +0.1 | +0.0 | +0.0 | +0.0 | -0.1 | +0.0 |
| 2026-07-03 | 3,045 | 3,110 | 🔴 +2.13% | — | ×0.5 | 🟢 외인 | +0.2억 | +0.2 | +0.0 | -0.0 | +0.0 | -0.2 | -0.0 |
| 2026-07-02 | 3,225 | 3,045 | 🔵 -5.58% | — | ×0.7 | 🔻 개인 | -1.4억 | -1.4 | +0.0 | +0.0 | +0.0 | +1.2 | +0.2 |
| 2026-07-01 | 3,270 | 3,225 | 🔵 -1.38% | — | ×0.5 | 🔻 개인 | -1.3억 | -1.3 | +0.0 | +0.0 | +0.0 | +1.3 | -0.0 |
| 2026-06-30 | 3,230 | 3,270 | 🔴 +1.24% | — | ×0.6 | 🔻 개인 | -0.2억 | -0.2 | +0.0 | +0.0 | +0.0 | +0.1 | +0.0 |
| 2026-06-29 | 2,995 | 3,230 | 🔴 +7.85% | — | ×1.0 | 🟢 외인 | +3.7억 | +3.7 | +0.0 | +0.0 | +0.0 | -3.7 | +0.0 |
| 2026-06-26 | 3,110 | 2,995 | 🔵 -3.70% | — | ×0.9 | 🔻 개인 | -0.3억 | -0.3 | +0.0 | +0.0 | +0.0 | +0.3 | +0.0 |
| 2026-06-25 | 3,190 | 3,110 | 🔵 -2.51% | — | ×0.5 | 🔻 개인 | -0.6억 | -0.6 | +0.0 | +0.0 | +0.0 | +0.6 | +0.0 |
일자별 사유 (최신 위)
2026-07-15
- 사유: —
- 섹터 컨텍스트: KOSDAQ:제조 (smart +1,144억)
- 매크로 원인: HLB 리보세라닙 FDA 제조 리스크 해소 기대에 그룹주 무더기 상한가, 미프진 허가 검토·항암신약 모멘텀 가세 (보통)